Radiopharm Theranostics Limited (RADX) AI Stock Analysis
RADX AI stock analysis summary
AI ResearchRadiopharm Theranostics Limited is a clinical-stage biotechnology company developing radiopharmaceutical products for diagnostic and therapeutic applications. For FY2026, the company generated $2.7M in revenue with a net income of -$53.9M. The stock closed at $1.03 on October 16, 2026, after falling 85.5% over the past year.
- Market cap
- $15.0M
- Revenue (TTM)
- $12.9M
- P/E
- —
- 1Y return
- -85.5% S&P 500 16.8%
- Avg. target
- $16.95 1546.1% vs last close
Bull case
- Wall Street analysts maintain 4 Strong Buy ratings and 1 Buy rating, with a mean price target of $16.95.
- The company delivered a 4-year revenue CAGR of 318.4% between FY2022 and FY2026.
- Analyst estimates project revenue growth of 2133.7% to $23.8M for the fiscal year ending after June 30, 2027.
Bear case
- The company generated a net loss of -$53.9M and negative operating cash flow of -$51.6M in FY2026.
- The stock fell 85.5% over the past year to close at $1.03 on October 16, 2026.
- Cash and short-term investments stood at $4.1M as of June 30, 2026, relative to FY2026 operating cash flow of -$51.6M.
What Radiopharm Theranostics Limited does
Radiopharm Theranostics Limited is a clinical-stage radiotherapeutics company that engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. Its pipeline includes RAD101 and RAD102 for brain metastasis, RAD201a and RAD202 for HER-2 breast cancer, and RAD203 and RAD204 for PDL1 non-small cell lung cancer. It is also developing RAD301 and RAD302 for pancreatic indications, as well as RAD401 and RAD402 for prostate cancer. Incorporated in 2021, the company is based in Carlton, Australia and employs 14 people.
Growth and profitability
Annual revenue grew from $8,831 in FY2022 to $292,359 in FY2023, reached $3.6M in FY2025, and fell 25.5% to $2.7M in FY2026. Across that period, the four-year revenue CAGR was 318.4%. Gross margin moved from 100.0% in FY2024 to 1.1% in FY2025 and -77.7% in FY2026. Annual net losses expanded from -$30.3M in FY2022 to -$53.9M in FY2026, while R&D expenses rose from $4.1M in FY2022 to $27.5M in FY2025. For the trailing twelve months, revenue was $12.9M with an operating margin of -400.3%, an EPS of -$3.64, and latest quarter revenue down 36.9% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, Radiopharm Theranostics held $4.1M in cash and short-term investments, with total assets of $60.1M and shareholders' equity of $24.7M. The current ratio stood at 1.16. In FY2026, operating cash flow was -$51.6M, compared to -$36.6M in FY2025. Cash use included capital expenditures of $51.6M during FY2026.
Valuation and performance
Radiopharm Theranostics carries a market cap of $15.0M and an enterprise value of $18.9M. The stock trades at a price-to-sales multiple of 1.2x, below the 4.1x median of its US-listed Healthcare peers, while its enterprise value-to-revenue ratio is 9.6x and price-to-book is 1.3x. Over the past year, the ADS fell 85.5%, compared to a 16.8% gain for the S&P 500 (SPY). The shares trade 73.4% below their 200-day average.
What analysts expect
Wall Street analysts cover the stock with 4 Strong Buy ratings and 1 Buy rating, with 0 Hold, Sell, or Strong Sell ratings. The mean price target is $16.95, which is 1546.1% above the last close of $1.03. For the fiscal year ending June 30, 2027, consensus estimates project revenue of $1.1M and an EPS of -$3.23. For the following fiscal year, revenue is projected at $23.8M with an EPS of -$2.64. Radiopharm Theranostics recorded 0 EPS beats over the last 4 quarters.
Key risks and what to watch
- Cash and short-term investments totaled $4.1M as of June 30, 2026, which is small relative to the -$51.6M of operating cash flow in FY2026.
- Gross margin turned negative to -77.7% in FY2026, accompanied by an operating margin of -2468.6%.
- Revenue declined 25.5% in FY2026 to $2.7M and fell 36.9% year-over-year in the quarter ended June 30, 2026.
- Radiopharm Theranostics recorded 0 EPS beats across the last 4 quarters.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this RADX AI stock analysis
This page is an AI-written research summary of Radiopharm Theranostics Limited (RADX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: RADX income statement, RADX analyst forecast, RADX chart. See the RADX stock overview for the latest quote and news.
RADX AI stock analysis FAQ
Does Radiopharm Theranostics pay a dividend?
No, Radiopharm Theranostics does not pay a dividend.
What is the consensus analyst price target for RADX?
The mean analyst price target is $16.95, representing a 1546.1% premium to its closing price of $1.03 on October 16, 2026.
What was Radiopharm Theranostics' revenue in FY2026?
In FY2026, Radiopharm Theranostics reported revenue of $2.7M, which represented a 25.5% decline from $3.6M in FY2025.
How much cash does the company have?
As of June 30, 2026, the company held $4.1M in cash and short-term investments, with a current ratio of 1.16.